Cover Image
市場調查報告書

全球PCOS治療藥市場

Global PCOS Drugs Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 301116
出版日期 內容資訊 英文 88 Pages
訂單完成後即時交付
價格
Back to Top
全球PCOS治療藥市場 Global PCOS Drugs Market 2014-2018
出版日期: 2014年04月25日 內容資訊: 英文 88 Pages
簡介

所謂PCOS,別名多囊性卵巢症候群,是女性最常見的荷爾蒙內分泌障礙之一。有多囊性卵巢,不規則或無月經高雄激素(男性荷爾蒙)等特徵,確切病因不明。這個障礙是指,由於無法充分分泌排卵的荷爾蒙而使卵巢產生複數的小囊胞,為了準備排卵而充滿液體的卵巢卵泡,無法排卵而維持卵泡停留在卵巢的狀態。現在可使用的PCOS治療方法,有改善生活方式、投藥、手術等。全球PCOS治療藥的市場預計從2013年到2018年以年平均成長率2.65%發展。

本報告提供全球PCOS治療藥市場現況與展望調查分析、目前市場環境、已上市治療藥的競爭趨勢、開發平台藥物的開發趨勢、產品的購買標準、影響市場成長因素、競爭環境、主要供應商的企業資料、產業策略等彙整資料,為您概述為以下內容。

為您概述為以下內容。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場環境

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 已販售產品的競爭分析

第8章 開發中產品的概要

第9章 罹患率和得病率

  • 南北美洲
  • 歐洲

第10章 地區區分

第11章 購買標準

第12章 市場促進因素

第13章 成長推進因素與其影響

第14章 市場上課題

第15章 成長推進因素及課題的影響

第16章 市場趨勢

第17章 市場趨勢與其影響

第18章 供應商環境

  • 競爭模式
    • 主要消息
    • M&A
  • 供應商分析
  • 其他的關注供應商

第19章 主要供應商分析

  • Sanofi SA
  • Bristol Myers Squibb Co.
  • Novartis A.G.
  • Teva Pharmaceutical Inc.
  • Merck & Co. Inc.
    • 主要資料
    • 產業概要
    • 產業區分
    • 各產業分類收益
    • 收益的轉變
    • 各地區銷售額
    • 產業策略
    • 主要的開發趨勢
    • SWOT分析等

第20章 本系列的其他報告

目錄
Product Code: IRTNTR3490

About PCOS Drugs

PCOS, also known as Stein-Leventhal Syndrome, is one of the most common hormonal endocrine disorders in women. It is characterized by polycystic ovaries, irregular or no menstrual periods, irregular ovulation, and high levels of androgens (male hormones) in the body. The exact cause of PCOS is unknown. In PCOS, small cysts form on the ovaries, which do not produce a sufficient amount of hormone to initiate ovulation. The ovarian follicles, which are filled with fluid in preparation for ovulation, remain as cysts when ovulation does not occur. Lifestyle modifications, medication, and surgery are some of the currently available treatments for PCOS.

TechNavio's analysts forecast the Global PCOS Drugs market will grow at a CAGR of 2.65 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global PCOS Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of marketed, off-label, and generic drugs used in the treatment of PCOS.

TechNavio's report, the Global PCOS Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PCOS Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Bristol Myers Squibb Co.
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi SA
  • Teva Pharmaceutical Inc.

Other Prominent Vendors

  • AstraZeneca plc
  • Catalysis SL
  • Crinetics Pharmaceuticals Inc.
  • Dexa Medica Group
  • EffRx Inc.
  • Neurocrine Biosciences Inc.

Market Driver

  • Increase in Patient Population.

For a full, detailed list, view our report.

Market Challenge

  • Lack of Approved Drugs.

For a full, detailed list, view our report.

Market Trend

  • Increase in Awareness of PCOS Drugs.

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Competitive Analysis of Marketed Products

08. Pipeline Snapshot

09. Rate of Incidence and Prevalence

  • 09.1.1. Americas
  • 09.1.2. Europe

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Vendors Analysis 2013
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Sanofi SA
    • 19.1.1. Key Facts
    • 19.1.2. Business Description
    • 19.1.3. Business Segmentation
    • 19.1.4. Revenue by Business Segmentation
    • 19.1.5. Revenue Comparison 2012 and 2013
    • 19.1.6. Sales by Geography
    • 19.1.7. Business Strategy
    • 19.1.8. Key Developments
    • 19.1.9. SWOT Analysis
    • 19.1.10. Strengths
    • 19.1.11. Weakness
    • 19.1.12. Opportunities
    • 19.1.13. Threats
  • 19.2. Bristol Myers Squibb Co.
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Key Product Offerings
    • 19.2.4. Sales by Geography
    • 19.2.5. Business Strategy
    • 19.2.6. Key Information
    • 19.2.7. SWOT Analysis
    • 19.2.8. Strengths
    • 19.2.9. Weaknesses
    • 19.2.10. Opportunities
    • 19.2.11. Threats
  • 19.3. Novartis A.G.
    • 19.3.1. Key Facts
    • 19.3.2. Business Description
    • 19.3.3. Business Segmentation
    • 19.3.4. Revenue by Business Segmentation
    • 19.3.5. Revenue Comparison 2012 and 2013
    • 19.3.6. Sales by Geography
    • 19.3.7. Business Strategy
    • 19.3.8. Key Developments
  • 19.4. SWOT Analysis
    • 19.4.1. Strengths
    • 19.4.2. Weaknesses
    • 19.4.3. Opportunities
    • 19.4.4. Threats
  • 19.5. Teva Pharmaceutical Inc.
    • 19.5.1. Key Facts
    • 19.5.2. Business Overview
    • 19.5.3. Business Segmentation
    • 19.5.4. Revenue by Business Segmentation
    • 19.5.5. Revenue Comparison 2012 and 2013
    • 19.5.6. Revenue Segmentation by Geography
    • 19.5.7. Business Strategy
    • 19.5.8. Key Developments
    • 19.5.9. SWOT Analysis
    • 19.5.10. Strengths
    • 19.5.11. Weakness
    • 19.5.12. Opportunities
    • 19.5.13. Threats
  • 19.6. Merck & Co. Inc.
    • 19.6.1. Key Facts
    • 19.6.2. Business Description
    • 19.6.3. Business Segmentation
    • 19.6.4. Revenue by Business Segmentation
    • 19.6.5. Revenue Comparison 2012 and 2013
    • 19.6.6. Sales by Geography
    • 19.6.7. Business Strategy
    • 19.6.8. Key Developments
    • 19.6.9. SWOT Analysis
    • 19.6.10. Strengths
    • 19.6.11. Weaknesses
    • 19.6.12. Opportunities
    • 19.6.13. Threats

20. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global PCOS Drugs Market 2013-2018 (US$ million)
  • Exhibit 3: Global PCOS Drugs Market by Geographical Segmentation 2013
  • Exhibit 4: Sanofi SA: Business Segmentation
  • Exhibit 5: Sanofi SA: Revenue by Business Segmentation 2013
  • Exhibit 6: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 7: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
  • Exhibit 8: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
  • Exhibit 9: Bristol-Myers Squibb Co.: Sales by Geographical Segmentation 2013
  • Exhibit 10: Novartis AG: Business Segmentation
  • Exhibit 11: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 12: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 13: Novartis AG: Revenue by Geographical Segmentation 2013
  • Exhibit 14: Teva Pharmaceutical Industries Ltd.: Business Segmentation
  • Exhibit 15: Teva Pharmaceutical Industries Ltd.: Revenue by Business Segmentation 2013
  • Exhibit 16: Teva Pharmaceutical Industries Ltd.: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 17: Teva Pharmaceutical Industries Ltd.: Revenue by Geographical Segmentation 2013
  • Exhibit 18: Merck & Co. Inc.: Business Segmentation 2013
  • Exhibit 19: Merck & Co. Inc.: Revenue by Business Segmentation 2013
  • Exhibit 20: Merck & Co. Inc.: Revenue by Business Segmentation 2012 and 2013 (US$ billion)
  • Exhibit 21: Merck & Co. Inc.: Revenue by Geographical Segmentation 2013
Back to Top